Form 4: Theravance Biopharma Executive Sells Shares to Cover Tax Obligations

A Theravance Biopharma executive, Brett A. Grimaud, sold 9,268 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Brett A. Grimaud, a Senior Vice President, General Counsel, and Secretary at Theravance Biopharma, Inc., sold 9,268 ordinary shares on November 20, 2024.
• The shares were sold at a price of $9.97 per share.
• This transaction was not an open market sale but rather a withholding of shares by the company to cover tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Mr. Grimaud beneficially owns 333,345 ordinary shares.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• Share sales by executives to cover tax obligations are a common practice across the pharmaceutical and biotech industries.
• Many companies use restricted stock units as part of their compensation packages, which often trigger tax liabilities upon vesting.
• The number of shares sold and the price are within the typical range for such transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the executive's confidence in the company.

Key Dates

Keywords

Theravance Biopharma, share sale, insider trading, Form 4, executive compensation, stock options, tax obligations, restricted stock units